

**A HUMAN PROTEIN WITH TRANSMEMBRANE DOMAINS
AND DNA ENCODING THE PROTEIN**

At page 17, please replace the paragraph starting at line 26 with the following:

Using the proteins of the invention it may also be possible to regulate immune responses in a number of ways. Down regulation may be in the form of inhibiting or blocking an immune response already in progress or may involve preventing the induction of an immune response. The functions of activated T cells may be inhibited by suppressing T cells responses or by inducing specific tolerance in T cells, or both. Immunosuppression of T cell responses is generally an active, non-antigen-specific process which requires continuous exposure of the T cells to the suppressive agent. Tolerance, which involves inducing non-responsiveness or anergy in T cells, is distinguishable from immunosuppression in that it is generally antigen-specific and persists after exposure to the tolerizing agent has ceased. Operationally, tolerance can be demonstrated by the lack of a T cell response upon re-exposure to specific antigen in the absence of the tolerizing agent.

At page 38, please replace the paragraph starting at line 27 with the following:

Cells from the histiocyte lymphoma cell line U937 (ATCC CRL 1593) stimulated with phorbol ester, cells from human stomach cancer tissues delivered by operation, and cells from human liver were used to extract mRNAs. The cell line was incubated by a conventional procedure.

In the claims:

Please cancel claims 23 and 26, and amend claims 8, 10, 12, 20, 21 and 24 as follows:

8. **(Amended)** An isolated nucleic acid comprising a nucleotide sequence that is at least 95% identical to the nucleotide sequence set forth in SEQ ID NO: 11.

9. **(Amended)** An isolated nucleic acid which encodes a naturally occurring allelic variant of a polypeptide consisting of the amino acid sequence set forth in SEQ ID

NO: 1, wherein the nucleic acid hybridizes in 4X SSC at 67° C, followed by one or more washes in 1X SSC, at 67° C to a complement of a nucleic acid having a nucleotide sequence set forth in SEQ ID NO: 11.

11. (**Amended**) An isolated nucleic acid molecule which encodes a fragment of a polypeptide consisting of the amino acid sequence of SEQ ID NO:1, wherein the fragment comprises at least 8 contiguous amino acid residues set forth in the amino acid sequence of SEQ ID NO:1.

12. (**Amended**) An isolated nucleic acid molecule which hybridizes to the nucleic acid molecule of any one of claims 7, 8, 9, 10, or 11 in 1X SSC at 65° C, followed by one or more washes in 0.3X SSC at 65° C.

20. (**Amended**) A fragment of a polypeptide consisting of the amino acid sequence set forth in SEQ ID NO:1, wherein said fragment comprises 8 or more contiguous amino acid residues of the amino acid sequence set forth in SEQ ID NO:1.

21. (**Amended**) An isolated polypeptide comprising of the amino acid sequence set forth in SEQ ID NO:1.

24. (**Amended**) A composition comprising the polypeptide of any one of claims 20, 21, and 22 and a pharmaceutically acceptable carrier.

Abstract of the Disclosure:

Please insert page 70, entitled "ABSTRACT" which is provided herewith on a separate page.